A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HB-adMSCs) for the Treatment of Alzheimer's Disease

• ClinicalTrials.gov Identifier: NCT04228666
• Recruitment Status: Withdrawn
• First Posted: January 14, 2020
• Last Update Posted: July 7, 2021
• Sponsor: Hope Biosciences Stem Cell Research Foundation
• Collaborator: Hope Biosciences
• Information provided by (Responsible Party): Hope Biosciences ( Hope Biosciences Stem Cell Research Foundation )

Study Description

Brief Summary:

Hope Biosciences is conducting a research study of an investigational product called autologous adipose-derived mesenchymal stem cells (abbreviated as HB-adMSCs) as a possible treatment for Alzheimer's disease (AD). The study purpose is to evaluate the safety profile of four IV infusions of HB-adMSCs in subjects with clinical diagnosis of AD.

Condition or disease	Intervention/treatment	Phase
Alzheimer Disease	Biological: HB-adMSCs	Phase 1; Phase 2

Detailed Description:

This is a Phase 1/2a, open-label, non-randomized study in subjects with Alzheimer's disease. 24 patients will be enrolled for the study. The overall objective of this study is to evaluate the safety profile of four IV infusions of autologous adipose-derived mesenchymal stem cells (HB-adMSCs) in subjects with clinical diagnosis of AD. The primary endpoint of this study is to measure the number and frequency of adverse event(s) and/or severe adverse event(s) throughout the study duration. The second endpoint of this study is to evaluate the ability of HB-adMSCs to alter AD-related inflammation via measuring levels of Tumor Necrosis Factor alpha (TNF-a), Interleukin-1 (IL-1), Interleukin-6 (IL-6), C-Reactive Protein (CRP), and markers associated with amyloid deposition, Amyloid beta 40 and Amyloid beta 42. Subjects will also be assessed for cognitive deficits measured by changes from baseline values using Mini Mental Status Examination (MMSE), Alzheimer's disease Cooperative Study Activities of Daily Living (ADCS-ADL), Alzheimer's disease Related Quality of Life (ADRQL), Altoida Neuro Motor Index (NMI) for Digital Biomarkers, and Clinical Dementia Rating Questionnaire (CDR).

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 0 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HB-adMSCs) for the Treatment of Alzheimer's Disease
• Actual Study Start Date: March 1, 2020
• Estimated Primary Completion Date: February 1, 2022
• Estimated Study Completion Date: February 1, 2022

Arms and Interventions

Arm

Intervention/treatment

Experimental: HB-adMSCs; HB-adMSCs are autologous, adipose-derived mesenchymal stem cells. Four intravenous infusions will be administered on weeks 0, 2, 6, and 8 at a dose of 2 x 10^8 total HB-adMSC cells.

Biological: HB-adMSCs; Four IV infusions of autologous adipose-derived mesenchymal stem cells. Baseline laboratory data will be collected prior to first infusion; follow-up data will be compared against baseline according to the following schedule: safety laboratory tests follow-up on weeks 4, 8, 13, 26, and 52; inflammation and amyloid markers follow-up on weeks 13 and 52; MMSE and ADCS-ADL follow-up on weeks 13, 19, 26, 33, 40, 46 and 52; Altoida NMI follow-up will occur weekly from week 0 to week 52; CDR follow-up will occur weeks 4, 10, 13, 19, 26, 33, 40, 46 and 52; C-SSRS follow-up will occur on weeks 4, 10, 26, and 52; Amyloid PET imaging follow-up occurs week 26 and 52;

Outcome Measures

Primary Outcome Measures :

1. Glucose [ Time Frame: Screening, change from screening at week 0, week 4, week 8, week 13, week 26, week 52. ]
   clinical lab evaluation of level of glucose in the blood (mg/dL)
2. Calcium [ Time Frame: Screening, change from screening at week 0, week 4, week 8, week 13, week 26, week 52. ]
   clinical lab evaluation of level of calcium in the blood (mg/dL)
3. Albumin [ Time Frame: Screening, change from screening at week 0, week 4, week 8, week 13, week 26, week 52. ]
   clinical lab evaluation of level of albumin in the blood (g/dL)
4. Total Protein [ Time Frame: Screening, change from screening at week 0, week 4, week 8, week 13, week 26, week 52. ]
   clinical lab evaluation of level of protein in the blood (g/dL)
5. Sodium [ Time Frame: Screening, change from screening at week 0, week 4, week 8, week 13, week 26, week 52. ]
   clinical lab evaluation of level of sodium in the blood (mol/L)
6. Total carbon dioxide [ Time Frame: Screening, change from screening at week 0, week 4, week 8, week 13, week 26, week 52. ]
   clinical lab evaluation of level of carbon dioxide in the blood (mmol/L)
7. Potassium [ Time Frame: Screening, change from screening at week 0, week 4, week 8, week 13, week 26, week 52. ]
   clinical lab evaluation of level of potassium in the blood (mmol/L)
8. Chloride [ Time Frame: Screening, change from screening at week 0, week 4, week 8, week 13, week 26, week 52. ]
   clinical lab evaluation of level of chloride in the blood (mmol/L)
9. BUN [ Time Frame: Screening, change from screening at week 0, week 4, week 8, week 13, week 26, week 52. ]
   clinical lab evaluation of level of BUN in the blood (mg/dL)
10. Creatinine [ Time Frame: Screening, change from screening at week 0, week 4, week 8, week 13, week 26, week 52. ]
    clinical lab evaluation of level of creatinine in the blood (mg/dL)
11. Alkaline phosphatase [ Time Frame: Screening, change from screening at week 0, week 4, week 8, week 13, week 26, week 52. ]
    clinical lab evaluation of level of alkaline phosphatase in the blood (IU/L)
12. Alanine aminotransferase [ Time Frame: Screening, change from screening at week 0, week 4, week 8, week 13, week 26, week 52. ]
    clinical lab evaluation of level of alanine aminotransferase in the blood (IU/L)
13. Aspartate aminotransferase [ Time Frame: Screening, change from screening at week 0, week 4, week 8, week 13, week 26, week 52. ]
    clinical lab evaluation of level of aspartate aminotransferase in the blood (IU/L)
14. Total Bilirubin [ Time Frame: Screening, change from screening at week 0, week 4, week 8, week 13, week 26, week 52. ]
    clinical lab evaluation of level of bilirubin in the blood (mg/dL)
15. White blood cell [ Time Frame: Screening, change from screening at week 0, week 4, week 8, week 13, week 26, week 52. ]
    clinical lab evaluation of level of white blood cells in the blood (x 10^3/uL)
16. Red blood cell [ Time Frame: Screening, change from screening at week 0, week 4, week 8, week 13, week 26, week 52. ]
    clinical lab evaluation of level of red blood cells in the blood (x 10^6/uL)
17. Hemoglobin [ Time Frame: Screening, change from screening at week 0, week 4, week 8, week 13, week 26, week 52. ]
    clinical lab evaluation of level of hemoglobin in the blood (g/dL)
18. Hematocrit [ Time Frame: Screening, change from screening at week 0, week 4, week 8, week 13, week 26, week 52. ]
    clinical lab evaluation of level of hematocrit in the blood (%)
19. Mean corpuscular volume [ Time Frame: Screening, change from screening at week 0, week 4, week 8, week 13, week 26, week 52. ]
    clinical lab evaluation of mean corpuscular volume in the blood (fL)
20. Mean corpuscular hemoglobin [ Time Frame: Screening, change from screening at week 0, week 4, week 8, week 13, week 26, week 52. ]
    clinical lab evaluation of mean corpuscular hemoglobin in the blood (pg)
21. Mean corpuscular hemoglobin concentration [ Time Frame: Screening, change from screening at week 0, week 4, week 8, week 13, week 26, week 52. ]
    clinical lab evaluation of level of hemoglobin concentration in the blood (g/dL)
22. Red cell distribution width [ Time Frame: Screening, change from screening at week 0, week 4, week 8, week 13, week 26, week 52. ]
    clinical lab evaluation of distribution width in the blood (%)
23. Neutrophils [ Time Frame: Screening, change from screening at week 0, week 4, week 8, week 13, week 26, week 52. ]
    clinical lab evaluation of neutrophils in the blood (%)
24. Lymphs [ Time Frame: Screening, change from screening at week 0, week 4, week 8, week 13, week 26, week 52. ]
    clinical lab evaluation of lymphocytes in the blood (%)
25. Monocytes [ Time Frame: Screening, change from screening at week 0, week 4, week 8, week 13, week 26, week 52. ]
    clinical lab evaluation of monocytes in the blood (%)
26. Eos [ Time Frame: Screening, change from screening at week 0, week 4, week 8, week 13, week 26, week 52. ]
    clinical lab evaluation of eosinophils in the blood (%)
27. Basophils [ Time Frame: Screening, change from screening at week 0, week 4, week 8, week 13, week 26, week 52. ]
    clinical lab evaluation of basophils in the blood (%)
28. Absolute neutrophils [ Time Frame: Screening, change from screening at week 0, week 4, week 8, week 13, week 26, week 52. ]
    clinical lab evaluation of absolute neutrophils in the blood (x 10^3/uL)
29. Absolute lymphs [ Time Frame: Screening, change from screening at week 0, week 4, week 8, week 13, week 26, week 52. ]
    clinical lab evaluation of absolute lymphocytes in the blood (x 10^3/uL)
30. Absolute monocytes [ Time Frame: Screening, change from screening at week 0, week 4, week 8, week 13, week 26, week 52. ]
    clinical lab evaluation of absolute monocytes in the blood (x 10^3/uL)
31. Absolute Eos [ Time Frame: Screening, change from screening at week 0, week 4, week 8, week 13, week 26, week 52. ]
    clinical lab evaluation of absolute eosinophils in the blood (x 10^3/uL)
32. Absolute Basos [ Time Frame: Screening, change from screening at week 0, week 4, week 8, week 13, week 26, week 52. ]
    clinical lab evaluation of absolute basophils in the blood (x 10^3/uL)
33. Immature granulocytes [ Time Frame: Screening, change from screening at week 0, week 4, week 8, week 13, week 26, week 52. ]
    clinical lab evaluation of granulocytes in the blood (%)
34. Absolute Immature granulocytes [ Time Frame: Screening, change from screening at week 0, week 4, week 8, week 13, week 26, week 52. ]
    clinical lab evaluation of absolute immature granulocytes in the blood (x 10^3/uL)
35. Platelets [ Time Frame: Screening, change from screening at week 0, week 4, week 8, week 13, week 26, week 52. ]
    clinical lab evaluation of platelets in the blood (x 10^3/uL)
36. Prothrombin time [ Time Frame: Screening, change from screening at week 0, week 4, week 8, week 13, week 26, week 52. ]
    clinical lab evaluation of time for blood to coagulate (seconds)
37. INR [ Time Frame: Screening, change from screening at week 0, week 4, week 8, week 13, week 26, week 52. ]
    clinical lab evaluation of international normalized ratio of blood coagulation (no unit)

Secondary Outcome Measures :

1. Tumor necrosis factor-alpha [ Time Frame: week 0, change from baseline at week 13, change from baseline at week 52 ]
   measure level of TNFa in blood (pg/ml)
2. Interleukin-1 [ Time Frame: week 0, change from baseline at week 13, change from baseline at week 52 ]
   measure of IL-1 in the blood (pg/ml)
3. Interleukin-6 [ Time Frame: week 0, change from baseline at week 13, change from baseline at week 52 ]
   measure of IL-6 in the blood (pg/ml)
4. C-reactive protein [ Time Frame: week 0, change from baseline at week 13, change from baseline at week 52 ]
   measure of CRP in the blood (mg/L)
5. Amyloid beta 40 [ Time Frame: week 0, change from baseline at week 13, change from baseline at week 52 ]
   measure of AB40 in the blood (pg/ml)
6. Amyloid beta 42 [ Time Frame: week 0, change from baseline at week 13, change from baseline at week 52 ]
   measure of AB42 in the blood (pg/ml)
7. Volumetric changes in hippocampus, ventriculus, and whole brain [ Time Frame: screening, week 26 and 52 ]
   volume change from screening
8. Mini Mental Status Exam [ Time Frame: week 0, change from baseline at week 4, 10, 13, 19, 26, 33, 40, 46, and 52 ]
   Change from baseline score; scores from 0 to 30, lower score indicates more severe dementia
9. Alzheimer's disease Cooperative Study Activities of Daily Living [ Time Frame: week 0, change from baseline at week 4, 10, 13, 19, 26, 33, 40, 46, and 52 ]
   Change from baseline score; scores from 0 to 53, lower score indicates greater functional impairment
10. Quality of Life Enjoyment and Satisfaction Questionnaire [ Time Frame: week 0, change from baseline at week 4, 10, 13, 19, 26, 33, 40, 46, and 52 ]
    Change from baseline score; total score range is 14 to 70, higher scores indicate more enjoyment and satisfaction with life
11. Altoida Neuro Motor Index [ Time Frame: week 0, change from baseline at week 4, 10, 13, 19, 26, 33, 40, 46, and 52 ]
    Change from baseline score; score ranges from 0 to 100, higher score indicates less impairment
12. Clinical Dementia Rating Questionnaire [ Time Frame: week 0, change from baseline at week 4, 10, 13, 19, 26, 33, 40, 46, and 52 ]
    Change from baseline score; scores range fro 0 to 3, higher scores indicates more severe impairment

Eligibility Criteria

• Ages Eligible for Study: 50 Years to 85 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Men, and women of non-childbearing potential, 50-85 years of age inclusively, with a diagnosis of early stage's (preclinical/mild cognitive impairment) Probable Alzheimer's Disease according to the 2011 NIA-AA criteria.

   • Non-childbearing potential for women is defined as postmenopausal [last natural menses greater than 24 months; in women under age 55, menopausal status will be documented with serum follicle stimulating hormone (FSH) test] or undergone a documented bilateral tubal ligation or hysterectomy.
   • Male participants who are sexually active with a woman of childbearing potential must agree to use condoms during the trial unless the woman is using an acceptable means of birth control. Acceptable forms of birth control include abstinence, birth control pills, or any double combination of intrauterine device (IUD), male or female condom and diaphragm.
2. Informed consent signed by the subject
3. Documented Amyloid PET Scan (images and report) positive to amyloid plaques deposits on the brain.
4. If the patient is under any treatment, should have been on a stable dose for at least 30 days prior to signing the informed consent form and there is no intention to modify the dose over the course of the study. (NOTE: Cholinesterase inhibitors (AChEI) (donepezil, galantamine, or rivastigmine) may not be initiated, discontinued or modified after study initiation for the 12-months control period).

Exclusion Criteria:

1. Hospitalization or change of chronic concomitant medication within one month prior to screening.

2. Clinically significant or unstable disease that may interfere with outcome evaluations, including but not limited to:

   • Respiratory Insufficiency
   • Poorly managed hypertension (systolic >160 mm Hg and/or diastolic >95 mm Hg) or hypotension (systolic <90 mm Hg and/or diastolic <60 mm Hg); or
   • Bradycardia (<50 beats/min.) or tachycardia (>100 beats/min.). Otherwise healthy subjects with borderline bradycardia may be discussed with the medical monitor to determine eligibility.
   • Renal insufficiency, defined as eGFR <40 mL/min based on the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) formula, https://www.mdcalc.com/ckd-epi-equations-glomerular-filtration-rate-gfr
   • Heart disease (myocardial infarction, unstable angina, heart failure, cardiomyopathy within 3 months before screening). If a subject has a history of heart disease of questionable clinical significance, the medical monitor may be contacted to discuss eligibility.
3. Records of PET Scan negative to Amyloid plaques deposition in the brain.
4. Suspected or known drug or alcohol abuse, i.e. more than approximately 60 g alcohol (approximately 1 liter of beer or 0.5 liter of wine) per day.
5. Acute intercurrent infections such as Hepatitis C Virus (HCV), Hepatitis B Virus (HBV), Human Immunodeficiency Virus (HIV) or Syphilis.
6. Contraindications for PET scanning, including implanted metallic devices (e.g. non-MRI-safe cardiac pacemaker or neurostimulator; some artificial joints metal pins; surgical clips; or other implanted metal parts), or claustrophobia or discomfort in confined spaces.
7. Is unable or unwilling to comply with protocol follow-up requirements.
8. Enrollment in another investigational study or intake of investigational drug within the previous 30 days.
9. Any condition, which in the opinion of the investigator or the sponsor makes the patient unsuitable for inclusion.

Contacts and Locations

Locations

United States, Texas

Clinical Trial Network

Houston, Texas, United States, 77074

Sponsors and Collaborators

Hope Biosciences Stem Cell Research Foundation

Hope Biosciences

Investigators

• Principal Investigator: Djamchid Lotfi, MD; Clinical Trial Network

More Information

• Responsible Party: Hope Biosciences Stem Cell Research Foundation
• ClinicalTrials.gov Identifier: NCT04228666
• Other Study ID Numbers: HBALZ01
• First Posted: January 14, 2020
• Last Update Posted: July 7, 2021
• Last Verified: February 2021

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Hope Biosciences ( Hope Biosciences Stem Cell Research Foundation ):

Alzheimer's disease; stem cells; adipose derived mesenchymal stem cells

Additional relevant MeSH terms:

Alzheimer Disease; Dementia; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Tauopathies; Neurodegenerative Diseases; Neurocognitive Disorders; Mental Disorders